Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist use.

ABSTRACT:

Aims

Published literature has raised concerns regarding a causal association between glucagon-like peptide 1 receptor agonist (GLP-1RA) use and thyroid cancer risk in adults. In this analysis, we evaluated the association between thyroid cancer risk and GLP-1RA use.

Materials and methods

Our evaluation included data from (i) 93 liraglutide or semaglutide phase 2 and 3 clinical trials, of which six were cardiovascular outcome trials (CVOTs); (ii) post-marketing surveillance from the Novo Nordisk safety database (evaluating data for liraglutide and semaglutide); and (iii) the US Merative™ MarketScan® Commercial Database. Hazard ratios (HRs) were estimated for overall thyroid cancer risk for treatment groups in the clinical trials and for individuals with type 2 diabetes treate

SUBMITTER: Vilsboll T 

PROVIDER: S-EPMC12803555 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature